Global Intrauterine Contraceptive

Intrauterine Contraceptive Comprehensive Study by Type (Hormonal Intrauterine Device, Copper Intrauterine Device), Age Group (Age 15-24, Age 25-34, Age 35-44, Above 44), End User (Hospitals, Gynecology Clinics, Community Health Care Centers, Others) Players and Region - Global Market Outlook to 2030

Intrauterine Contraceptive Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Intrauterine Contraceptive
An intrauterine contraceptive device (IUD) is a tiny device that's put into uterus to prevent pregnancy. This is a long-term, reversible, and one of the most effective birth control methods. It is a minor piece of flexible plastic shaped like a T. Although these device provide protection for many years, they can be removed earlier. It is a quick process, in which a doctor gently pulls on the string, and the IUD's arms fold up so it slips out. However, the lack of social acceptance regarding contraceptive and adverse effects associated with use of intrauterine contraceptive devices are the factors hampering the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Intrauterine Contraceptive market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan PLC (Ireland), Bayer AG (Germany), CooperSurgical Inc. (United States), Egemen International (Turkey), Mona Lisa N.V. (Belgium), Pregna International Limited (India), Mylan (United States), Prosan International BV (Netherlands), SMB Corporation of India (India), Medisafe Distribution Inc (Canada) and Eurogine (Spain) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Intrauterine Contraceptive market by Type (Hormonal Intrauterine Device and Copper Intrauterine Device) and Region.



On the basis of geography, the market of Intrauterine Contraceptive has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Age Group, the sub-segment i.e. Age 15-24 will boost the Intrauterine Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Intrauterine Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Contraceptive Methods

Market Growth Drivers:
Rise In Government and NGO Initiatives to Promote Intrauterine Contraceptive Devices and Rising Need for Preventing Unwanted Pregnancy

Challenges:
Adverse Effects Associated With Use of Intrauterine Contraceptive Devices

Restraints:
Lack of Social Acceptance Regarding Contraceptive

Opportunities:
Increasing Awareness about Contraceptives across the Globe and Rise in Disposable Income and Demand for Healthy Life in Developing Countries

Market Leaders and their expansionary development strategies
On July 29, 2019 - HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. and Pfizer Inc. has announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.


Key Target Audience
Manufacturers of Intrauterine Contraceptive Device, Suppliers of Raw Materials, Distributors, and Retailers of Intrauterine Contraceptive Device, Healthcare Industry, Governmental Bodies and Research Firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Hormonal Intrauterine Device
  • Copper Intrauterine Device
By Age Group
  • Age 15-24
  • Age 25-34
  • Age 35-44
  • Above 44

By End User
  • Hospitals
  • Gynecology Clinics
  • Community Health Care Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise In Government and NGO Initiatives to Promote Intrauterine Contraceptive Devices
      • 3.2.2. Rising Need for Preventing Unwanted Pregnancy
    • 3.3. Market Challenges
      • 3.3.1. Adverse Effects Associated With Use of Intrauterine Contraceptive Devices
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Contraceptive Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intrauterine Contraceptive, by Type, Age Group, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Intrauterine Contraceptive (Value)
      • 5.2.1. Global Intrauterine Contraceptive by: Type (Value)
        • 5.2.1.1. Hormonal Intrauterine Device
        • 5.2.1.2. Copper Intrauterine Device
      • 5.2.2. Global Intrauterine Contraceptive by: Age Group (Value)
        • 5.2.2.1. Age 15-24
        • 5.2.2.2. Age 25-34
        • 5.2.2.3. Age 35-44
        • 5.2.2.4. Above 44
      • 5.2.3. Global Intrauterine Contraceptive by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Gynecology Clinics
        • 5.2.3.3. Community Health Care Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Intrauterine Contraceptive Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Intrauterine Contraceptive (Volume)
      • 5.3.1. Global Intrauterine Contraceptive by: Type (Volume)
        • 5.3.1.1. Hormonal Intrauterine Device
        • 5.3.1.2. Copper Intrauterine Device
      • 5.3.2. Global Intrauterine Contraceptive by: Age Group (Volume)
        • 5.3.2.1. Age 15-24
        • 5.3.2.2. Age 25-34
        • 5.3.2.3. Age 35-44
        • 5.3.2.4. Above 44
      • 5.3.3. Global Intrauterine Contraceptive by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Gynecology Clinics
        • 5.3.3.3. Community Health Care Centers
        • 5.3.3.4. Others
      • 5.3.4. Global Intrauterine Contraceptive Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Intrauterine Contraceptive (Price)
      • 5.4.1. Global Intrauterine Contraceptive by: Type (Price)
  • 6. Intrauterine Contraceptive: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan PLC (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CooperSurgical Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Egemen International (Turkey)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mona Lisa N.V. (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pregna International Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Prosan International BV (Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. SMB Corporation of India (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medisafe Distribution Inc (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eurogine (Spain)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Intrauterine Contraceptive Sale, by Type, Age Group, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Intrauterine Contraceptive (Value)
      • 7.2.1. Global Intrauterine Contraceptive by: Type (Value)
        • 7.2.1.1. Hormonal Intrauterine Device
        • 7.2.1.2. Copper Intrauterine Device
      • 7.2.2. Global Intrauterine Contraceptive by: Age Group (Value)
        • 7.2.2.1. Age 15-24
        • 7.2.2.2. Age 25-34
        • 7.2.2.3. Age 35-44
        • 7.2.2.4. Above 44
      • 7.2.3. Global Intrauterine Contraceptive by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Gynecology Clinics
        • 7.2.3.3. Community Health Care Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Intrauterine Contraceptive Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Intrauterine Contraceptive (Volume)
      • 7.3.1. Global Intrauterine Contraceptive by: Type (Volume)
        • 7.3.1.1. Hormonal Intrauterine Device
        • 7.3.1.2. Copper Intrauterine Device
      • 7.3.2. Global Intrauterine Contraceptive by: Age Group (Volume)
        • 7.3.2.1. Age 15-24
        • 7.3.2.2. Age 25-34
        • 7.3.2.3. Age 35-44
        • 7.3.2.4. Above 44
      • 7.3.3. Global Intrauterine Contraceptive by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Gynecology Clinics
        • 7.3.3.3. Community Health Care Centers
        • 7.3.3.4. Others
      • 7.3.4. Global Intrauterine Contraceptive Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Intrauterine Contraceptive (Price)
      • 7.4.1. Global Intrauterine Contraceptive by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intrauterine Contraceptive: by Type(USD Million)
  • Table 2. Intrauterine Contraceptive Hormonal Intrauterine Device , by Region USD Million (2018-2023)
  • Table 3. Intrauterine Contraceptive Copper Intrauterine Device , by Region USD Million (2018-2023)
  • Table 4. Intrauterine Contraceptive: by Age Group(USD Million)
  • Table 5. Intrauterine Contraceptive Age 15-24 , by Region USD Million (2018-2023)
  • Table 6. Intrauterine Contraceptive Age 25-34 , by Region USD Million (2018-2023)
  • Table 7. Intrauterine Contraceptive Age 35-44 , by Region USD Million (2018-2023)
  • Table 8. Intrauterine Contraceptive Above 44 , by Region USD Million (2018-2023)
  • Table 9. Intrauterine Contraceptive: by End User(USD Million)
  • Table 10. Intrauterine Contraceptive Hospitals , by Region USD Million (2018-2023)
  • Table 11. Intrauterine Contraceptive Gynecology Clinics , by Region USD Million (2018-2023)
  • Table 12. Intrauterine Contraceptive Community Health Care Centers , by Region USD Million (2018-2023)
  • Table 13. Intrauterine Contraceptive Others , by Region USD Million (2018-2023)
  • Table 14. South America Intrauterine Contraceptive, by Country USD Million (2018-2023)
  • Table 15. South America Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 16. South America Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 17. South America Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 18. Brazil Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 19. Brazil Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 20. Brazil Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 21. Argentina Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 22. Argentina Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 23. Argentina Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 24. Rest of South America Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 26. Rest of South America Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 27. Asia Pacific Intrauterine Contraceptive, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 30. Asia Pacific Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 31. China Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 32. China Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 33. China Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 34. Japan Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 35. Japan Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 36. Japan Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 37. India Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 38. India Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 39. India Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 40. South Korea Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 41. South Korea Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 42. South Korea Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 43. Taiwan Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 44. Taiwan Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 45. Taiwan Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 46. Australia Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 47. Australia Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 48. Australia Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 52. Europe Intrauterine Contraceptive, by Country USD Million (2018-2023)
  • Table 53. Europe Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 54. Europe Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 55. Europe Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 56. Germany Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 57. Germany Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 58. Germany Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 59. France Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 60. France Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 61. France Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 62. Italy Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 63. Italy Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 64. Italy Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 65. United Kingdom Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 67. United Kingdom Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 68. Netherlands Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 69. Netherlands Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 70. Netherlands Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 71. Rest of Europe Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 73. Rest of Europe Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 74. MEA Intrauterine Contraceptive, by Country USD Million (2018-2023)
  • Table 75. MEA Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 76. MEA Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 77. MEA Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 78. Middle East Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 79. Middle East Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 80. Middle East Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 81. Africa Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 82. Africa Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 83. Africa Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 84. North America Intrauterine Contraceptive, by Country USD Million (2018-2023)
  • Table 85. North America Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 86. North America Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 87. North America Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 88. United States Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 89. United States Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 90. United States Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 91. Canada Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 92. Canada Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 93. Canada Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 94. Mexico Intrauterine Contraceptive, by Type USD Million (2018-2023)
  • Table 95. Mexico Intrauterine Contraceptive, by Age Group USD Million (2018-2023)
  • Table 96. Mexico Intrauterine Contraceptive, by End User USD Million (2018-2023)
  • Table 97. Intrauterine Contraceptive Sales: by Type(K Units)
  • Table 98. Intrauterine Contraceptive Sales Hormonal Intrauterine Device , by Region K Units (2018-2023)
  • Table 99. Intrauterine Contraceptive Sales Copper Intrauterine Device , by Region K Units (2018-2023)
  • Table 100. Intrauterine Contraceptive Sales: by Age Group(K Units)
  • Table 101. Intrauterine Contraceptive Sales Age 15-24 , by Region K Units (2018-2023)
  • Table 102. Intrauterine Contraceptive Sales Age 25-34 , by Region K Units (2018-2023)
  • Table 103. Intrauterine Contraceptive Sales Age 35-44 , by Region K Units (2018-2023)
  • Table 104. Intrauterine Contraceptive Sales Above 44 , by Region K Units (2018-2023)
  • Table 105. Intrauterine Contraceptive Sales: by End User(K Units)
  • Table 106. Intrauterine Contraceptive Sales Hospitals , by Region K Units (2018-2023)
  • Table 107. Intrauterine Contraceptive Sales Gynecology Clinics , by Region K Units (2018-2023)
  • Table 108. Intrauterine Contraceptive Sales Community Health Care Centers , by Region K Units (2018-2023)
  • Table 109. Intrauterine Contraceptive Sales Others , by Region K Units (2018-2023)
  • Table 110. South America Intrauterine Contraceptive Sales, by Country K Units (2018-2023)
  • Table 111. South America Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 112. South America Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 113. South America Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 114. Brazil Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 115. Brazil Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 116. Brazil Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 117. Argentina Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 118. Argentina Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 119. Argentina Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 120. Rest of South America Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 121. Rest of South America Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 122. Rest of South America Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 123. Asia Pacific Intrauterine Contraceptive Sales, by Country K Units (2018-2023)
  • Table 124. Asia Pacific Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 125. Asia Pacific Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 126. Asia Pacific Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 127. China Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 128. China Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 129. China Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 130. Japan Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 131. Japan Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 132. Japan Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 133. India Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 134. India Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 135. India Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 136. South Korea Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 137. South Korea Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 138. South Korea Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 139. Taiwan Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 140. Taiwan Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 141. Taiwan Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 142. Australia Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 143. Australia Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 144. Australia Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 145. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 146. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 147. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 148. Europe Intrauterine Contraceptive Sales, by Country K Units (2018-2023)
  • Table 149. Europe Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 150. Europe Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 151. Europe Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 152. Germany Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 153. Germany Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 154. Germany Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 155. France Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 156. France Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 157. France Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 158. Italy Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 159. Italy Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 160. Italy Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 161. United Kingdom Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 162. United Kingdom Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 163. United Kingdom Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 164. Netherlands Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 165. Netherlands Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 166. Netherlands Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 167. Rest of Europe Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 168. Rest of Europe Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 169. Rest of Europe Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 170. MEA Intrauterine Contraceptive Sales, by Country K Units (2018-2023)
  • Table 171. MEA Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 172. MEA Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 173. MEA Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 174. Middle East Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 175. Middle East Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 176. Middle East Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 177. Africa Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 178. Africa Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 179. Africa Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 180. North America Intrauterine Contraceptive Sales, by Country K Units (2018-2023)
  • Table 181. North America Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 182. North America Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 183. North America Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 184. United States Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 185. United States Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 186. United States Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 187. Canada Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 188. Canada Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 189. Canada Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 190. Mexico Intrauterine Contraceptive Sales, by Type K Units (2018-2023)
  • Table 191. Mexico Intrauterine Contraceptive Sales, by Age Group K Units (2018-2023)
  • Table 192. Mexico Intrauterine Contraceptive Sales, by End User K Units (2018-2023)
  • Table 193. Intrauterine Contraceptive: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Intrauterine Contraceptive: by Type(USD Million)
  • Table 206. Intrauterine Contraceptive Hormonal Intrauterine Device , by Region USD Million (2025-2030)
  • Table 207. Intrauterine Contraceptive Copper Intrauterine Device , by Region USD Million (2025-2030)
  • Table 208. Intrauterine Contraceptive: by Age Group(USD Million)
  • Table 209. Intrauterine Contraceptive Age 15-24 , by Region USD Million (2025-2030)
  • Table 210. Intrauterine Contraceptive Age 25-34 , by Region USD Million (2025-2030)
  • Table 211. Intrauterine Contraceptive Age 35-44 , by Region USD Million (2025-2030)
  • Table 212. Intrauterine Contraceptive Above 44 , by Region USD Million (2025-2030)
  • Table 213. Intrauterine Contraceptive: by End User(USD Million)
  • Table 214. Intrauterine Contraceptive Hospitals , by Region USD Million (2025-2030)
  • Table 215. Intrauterine Contraceptive Gynecology Clinics , by Region USD Million (2025-2030)
  • Table 216. Intrauterine Contraceptive Community Health Care Centers , by Region USD Million (2025-2030)
  • Table 217. Intrauterine Contraceptive Others , by Region USD Million (2025-2030)
  • Table 218. South America Intrauterine Contraceptive, by Country USD Million (2025-2030)
  • Table 219. South America Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 220. South America Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 221. South America Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 222. Brazil Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 223. Brazil Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 224. Brazil Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 225. Argentina Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 226. Argentina Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 227. Argentina Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 228. Rest of South America Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 229. Rest of South America Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 230. Rest of South America Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 231. Asia Pacific Intrauterine Contraceptive, by Country USD Million (2025-2030)
  • Table 232. Asia Pacific Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 233. Asia Pacific Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 234. Asia Pacific Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 235. China Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 236. China Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 237. China Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 238. Japan Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 239. Japan Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 240. Japan Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 241. India Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 242. India Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 243. India Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 244. South Korea Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 245. South Korea Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 246. South Korea Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 247. Taiwan Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 248. Taiwan Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 249. Taiwan Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 250. Australia Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 251. Australia Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 252. Australia Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 256. Europe Intrauterine Contraceptive, by Country USD Million (2025-2030)
  • Table 257. Europe Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 258. Europe Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 259. Europe Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 260. Germany Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 261. Germany Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 262. Germany Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 263. France Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 264. France Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 265. France Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 266. Italy Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 267. Italy Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 268. Italy Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 269. United Kingdom Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 270. United Kingdom Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 271. United Kingdom Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 272. Netherlands Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 273. Netherlands Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 274. Netherlands Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 275. Rest of Europe Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 276. Rest of Europe Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 277. Rest of Europe Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 278. MEA Intrauterine Contraceptive, by Country USD Million (2025-2030)
  • Table 279. MEA Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 280. MEA Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 281. MEA Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 282. Middle East Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 283. Middle East Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 284. Middle East Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 285. Africa Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 286. Africa Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 287. Africa Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 288. North America Intrauterine Contraceptive, by Country USD Million (2025-2030)
  • Table 289. North America Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 290. North America Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 291. North America Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 292. United States Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 293. United States Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 294. United States Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 295. Canada Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 296. Canada Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 297. Canada Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 298. Mexico Intrauterine Contraceptive, by Type USD Million (2025-2030)
  • Table 299. Mexico Intrauterine Contraceptive, by Age Group USD Million (2025-2030)
  • Table 300. Mexico Intrauterine Contraceptive, by End User USD Million (2025-2030)
  • Table 301. Intrauterine Contraceptive Sales: by Type(K Units)
  • Table 302. Intrauterine Contraceptive Sales Hormonal Intrauterine Device , by Region K Units (2025-2030)
  • Table 303. Intrauterine Contraceptive Sales Copper Intrauterine Device , by Region K Units (2025-2030)
  • Table 304. Intrauterine Contraceptive Sales: by Age Group(K Units)
  • Table 305. Intrauterine Contraceptive Sales Age 15-24 , by Region K Units (2025-2030)
  • Table 306. Intrauterine Contraceptive Sales Age 25-34 , by Region K Units (2025-2030)
  • Table 307. Intrauterine Contraceptive Sales Age 35-44 , by Region K Units (2025-2030)
  • Table 308. Intrauterine Contraceptive Sales Above 44 , by Region K Units (2025-2030)
  • Table 309. Intrauterine Contraceptive Sales: by End User(K Units)
  • Table 310. Intrauterine Contraceptive Sales Hospitals , by Region K Units (2025-2030)
  • Table 311. Intrauterine Contraceptive Sales Gynecology Clinics , by Region K Units (2025-2030)
  • Table 312. Intrauterine Contraceptive Sales Community Health Care Centers , by Region K Units (2025-2030)
  • Table 313. Intrauterine Contraceptive Sales Others , by Region K Units (2025-2030)
  • Table 314. South America Intrauterine Contraceptive Sales, by Country K Units (2025-2030)
  • Table 315. South America Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 316. South America Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 317. South America Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 318. Brazil Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 319. Brazil Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 320. Brazil Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 321. Argentina Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 322. Argentina Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 323. Argentina Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 324. Rest of South America Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 325. Rest of South America Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 326. Rest of South America Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 327. Asia Pacific Intrauterine Contraceptive Sales, by Country K Units (2025-2030)
  • Table 328. Asia Pacific Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 329. Asia Pacific Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 330. Asia Pacific Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 331. China Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 332. China Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 333. China Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 334. Japan Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 335. Japan Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 336. Japan Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 337. India Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 338. India Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 339. India Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 340. South Korea Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 341. South Korea Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 342. South Korea Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 343. Taiwan Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 344. Taiwan Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 345. Taiwan Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 346. Australia Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 347. Australia Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 348. Australia Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 349. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 350. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 351. Rest of Asia-Pacific Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 352. Europe Intrauterine Contraceptive Sales, by Country K Units (2025-2030)
  • Table 353. Europe Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 354. Europe Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 355. Europe Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 356. Germany Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 357. Germany Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 358. Germany Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 359. France Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 360. France Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 361. France Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 362. Italy Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 363. Italy Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 364. Italy Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 365. United Kingdom Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 366. United Kingdom Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 367. United Kingdom Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 368. Netherlands Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 369. Netherlands Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 370. Netherlands Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 371. Rest of Europe Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 372. Rest of Europe Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 373. Rest of Europe Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 374. MEA Intrauterine Contraceptive Sales, by Country K Units (2025-2030)
  • Table 375. MEA Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 376. MEA Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 377. MEA Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 378. Middle East Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 379. Middle East Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 380. Middle East Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 381. Africa Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 382. Africa Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 383. Africa Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 384. North America Intrauterine Contraceptive Sales, by Country K Units (2025-2030)
  • Table 385. North America Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 386. North America Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 387. North America Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 388. United States Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 389. United States Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 390. United States Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 391. Canada Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 392. Canada Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 393. Canada Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 394. Mexico Intrauterine Contraceptive Sales, by Type K Units (2025-2030)
  • Table 395. Mexico Intrauterine Contraceptive Sales, by Age Group K Units (2025-2030)
  • Table 396. Mexico Intrauterine Contraceptive Sales, by End User K Units (2025-2030)
  • Table 397. Intrauterine Contraceptive: by Type(USD/Units)
  • Table 398. Research Programs/Design for This Report
  • Table 399. Key Data Information from Secondary Sources
  • Table 400. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intrauterine Contraceptive: by Type USD Million (2018-2023)
  • Figure 5. Global Intrauterine Contraceptive: by Age Group USD Million (2018-2023)
  • Figure 6. Global Intrauterine Contraceptive: by End User USD Million (2018-2023)
  • Figure 7. South America Intrauterine Contraceptive Share (%), by Country
  • Figure 8. Asia Pacific Intrauterine Contraceptive Share (%), by Country
  • Figure 9. Europe Intrauterine Contraceptive Share (%), by Country
  • Figure 10. MEA Intrauterine Contraceptive Share (%), by Country
  • Figure 11. North America Intrauterine Contraceptive Share (%), by Country
  • Figure 12. Global Intrauterine Contraceptive: by Type K Units (2018-2023)
  • Figure 13. Global Intrauterine Contraceptive: by Age Group K Units (2018-2023)
  • Figure 14. Global Intrauterine Contraceptive: by End User K Units (2018-2023)
  • Figure 15. South America Intrauterine Contraceptive Share (%), by Country
  • Figure 16. Asia Pacific Intrauterine Contraceptive Share (%), by Country
  • Figure 17. Europe Intrauterine Contraceptive Share (%), by Country
  • Figure 18. MEA Intrauterine Contraceptive Share (%), by Country
  • Figure 19. North America Intrauterine Contraceptive Share (%), by Country
  • Figure 20. Global Intrauterine Contraceptive: by Type USD/Units (2018-2023)
  • Figure 21. Global Intrauterine Contraceptive share by Players 2023 (%)
  • Figure 22. Global Intrauterine Contraceptive share by Players (Top 3) 2023(%)
  • Figure 23. Global Intrauterine Contraceptive share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan PLC (Ireland) Revenue: by Geography 2023
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 29. CooperSurgical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. CooperSurgical Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Egemen International (Turkey) Revenue, Net Income and Gross profit
  • Figure 32. Egemen International (Turkey) Revenue: by Geography 2023
  • Figure 33. Mona Lisa N.V. (Belgium) Revenue, Net Income and Gross profit
  • Figure 34. Mona Lisa N.V. (Belgium) Revenue: by Geography 2023
  • Figure 35. Pregna International Limited (India) Revenue, Net Income and Gross profit
  • Figure 36. Pregna International Limited (India) Revenue: by Geography 2023
  • Figure 37. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mylan (United States) Revenue: by Geography 2023
  • Figure 39. Prosan International BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 40. Prosan International BV (Netherlands) Revenue: by Geography 2023
  • Figure 41. SMB Corporation of India (India) Revenue, Net Income and Gross profit
  • Figure 42. SMB Corporation of India (India) Revenue: by Geography 2023
  • Figure 43. Medisafe Distribution Inc (Canada) Revenue, Net Income and Gross profit
  • Figure 44. Medisafe Distribution Inc (Canada) Revenue: by Geography 2023
  • Figure 45. Eurogine (Spain) Revenue, Net Income and Gross profit
  • Figure 46. Eurogine (Spain) Revenue: by Geography 2023
  • Figure 47. Global Intrauterine Contraceptive: by Type USD Million (2025-2030)
  • Figure 48. Global Intrauterine Contraceptive: by Age Group USD Million (2025-2030)
  • Figure 49. Global Intrauterine Contraceptive: by End User USD Million (2025-2030)
  • Figure 50. South America Intrauterine Contraceptive Share (%), by Country
  • Figure 51. Asia Pacific Intrauterine Contraceptive Share (%), by Country
  • Figure 52. Europe Intrauterine Contraceptive Share (%), by Country
  • Figure 53. MEA Intrauterine Contraceptive Share (%), by Country
  • Figure 54. North America Intrauterine Contraceptive Share (%), by Country
  • Figure 55. Global Intrauterine Contraceptive: by Type K Units (2025-2030)
  • Figure 56. Global Intrauterine Contraceptive: by Age Group K Units (2025-2030)
  • Figure 57. Global Intrauterine Contraceptive: by End User K Units (2025-2030)
  • Figure 58. South America Intrauterine Contraceptive Share (%), by Country
  • Figure 59. Asia Pacific Intrauterine Contraceptive Share (%), by Country
  • Figure 60. Europe Intrauterine Contraceptive Share (%), by Country
  • Figure 61. MEA Intrauterine Contraceptive Share (%), by Country
  • Figure 62. North America Intrauterine Contraceptive Share (%), by Country
  • Figure 63. Global Intrauterine Contraceptive: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan PLC (Ireland)
  • Bayer AG (Germany)
  • CooperSurgical Inc. (United States)
  • Egemen International (Turkey)
  • Mona Lisa N.V. (Belgium)
  • Pregna International Limited (India)
  • Mylan (United States)
  • Prosan International BV (Netherlands)
  • SMB Corporation of India (India)
  • Medisafe Distribution Inc (Canada)
  • Eurogine (Spain)
Select User Access Type

Key Highlights of Report


Mar 2024 249 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Intrauterine Contraceptive Quantitative research analysis
Global Intrauterine Contraceptive Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan PLC (Ireland), Bayer AG (Germany), CooperSurgical Inc. (United States), Egemen International (Turkey), Mona Lisa N.V. (Belgium), Pregna International Limited (India), Mylan (United States), Prosan International BV (Netherlands), SMB Corporation of India (India), Medisafe Distribution Inc (Canada) and Eurogine (Spain) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Contraceptive Methods" is seen as one of major influencing trends for Intrauterine Contraceptive Market during projected period 2023-2030.
The Intrauterine Contraceptive market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Intrauterine Contraceptive Report?

Have a Query? Click Here

Other Related Reports

Arthroscope Comprehensive Study by Type (Diagnostic Arthroscope, Diagnostic/Operating Arthroscope), Application (Arthritis Surgery, Synovitis surgery, Others), Exanimating Parts (Knee, Shoulder, Elbo...
$ 3450
Angiography Devices Comprehensive Study by Type (X-Ray Angiography Devices, CT Angiography Devices, MR Angiography Devices), Application (Diagnostic, Therapeutic), Indication (Known Suspected CAD, Va...
$ 3750
Plastic Surgery Instrument Comprehensive Study by Type (Handheld Instruments (Forceps, Scissors, Needle Holders, Retractors, Other), Electrosurgical Instruments (Bipolar Instruments, Monopolar Instru...
$ 3750
Cardiac Defibrillator Comprehensive Study by Type (Implantable Cardioverter Defibrillator (S-ICD, T-ICD), External Defibrillator (Manual, Automated, Wearable)), Application (Hospitals, Specialty Clin...
$ 3350
Respiratory Gas Monitors Comprehensive Study by Type (Stationary Gas Monitors, Mobile Gas Monitors), Application (Hospital, Clinic, Physical Examination Center, Others) Players and Region - Global Ma...
$ 3500
Portable Video Laryngoscope Comprehensive Study by Type (Micro hand held units, Larger units), Application (Emergency Department, Operating Rooms, Rapid response applications), Blade Size (Laryngosco...
$ 3800